IDSA vs ILADS: The Lyme Disease Guideline War and What It Means for Patients

At a Glance

Few disputes in infectious disease medicine have generated as much heat as the conflict between the Infectious Diseases Society of America (IDSA) and the International Lyme and Associated Diseases Society (ILADS). Both groups include credentialed physicians. Both cite peer-reviewed literature. Yet their published guidelines reach nearly opposite conclusions on the most clinically important questions: how long to treat, what to do when treatment fails, and whether persistent post-treatment symptoms represent cured patients with residual inflammation or incompletely treated patients with ongoing infection.

This matters far beyond academic debate. Insurance companies use the IDSA guidelines to justify denial of extended treatment. State medical boards in the United States have disciplined and even revoked the licenses of physicians who followed ILADS protocols. And millions of patients who continue to suffer after standard therapy find themselves in a no-man’s-land where their symptoms are real, their tests are negative, and their physicians are unwilling or legally unable to offer further treatment.

I have spent decades treating patients who fall into this gap. Here is my reading of the evidence.

The Core Scientific Disagreement

The central question is deceptively simple: does Borrelia burgdorferi persist in the body after a standard course of antibiotics?

The IDSA position, stated in its 2006 guidelines (endorsed without major change in its 2020 update) and in affiliated commentary in the clinical literature, is that standard therapy reliably eradicates the organism and that “post-treatment Lyme disease syndrome” (PTLDS) is an inflammatory phenomenon — an immune response that continues after the infection has resolved [1]. Under this framework, retreatment exposes patients to antibiotic risk without benefit.

The ILADS position, published as clinical guidelines in 2004 and updated in 2014, is that Borrelia has well-documented biological mechanisms that allow it to evade host immunity and antibiotic killing, that animal models demonstrate persistent viable organisms after standard courses, and that at least a subgroup of patients has ongoing infection requiring individualized extended therapy [2].

Both positions are defensible at the level they are arguing. The disagreement is partly about which evidence to weight.

What the NIH-Funded RCTs Actually Show

Four randomized controlled trials, most of them NIH-funded, examined extended antibiotic therapy for PTLDS. The IDSA cites these as definitive evidence against retreatment. ILADS argues the same trials are more equivocal.

The Klempner trial (2001) found no functional benefit from 90 days of IV ceftriaxone followed by oral doxycycline [3]. The Krupp trial (2003) found that IV ceftriaxone improved fatigue but not cognitive function [4]. The Fallon Columbia trial (2008) found short-term cognitive improvement with IV ceftriaxone that was not sustained at 24 weeks [5]. The Berende randomized trial (2016) in the Netherlands found no significant difference between extended versus shorter antibiotic courses, though patients in both treatment groups improved compared to placebo, which is a finding the IDSA position tends to minimize [6].

ILADS’s critique of these trials — shared by several independent methodologists — includes: exclusion criteria that likely screened out the sickest patients most likely to benefit; short follow-up windows; the use of IV ceftriaxone (a drug without good tissue penetration into biofilm-protected niches) rather than combination oral regimens; and the absence of objective biological endpoints. These are legitimate methodological points. The trials are informative; they are not dispositive.

The Persistence Literature the IDSA Underweights

The mechanistic case for Borrelia persistence is substantial. It is based not on anecdote but on replicable laboratory findings:

Biofilm formation. B. burgdorferi forms structured biofilms in vitro and in vivo that are orders of magnitude more resistant to antibiotic killing than planktonic spirochetes [7]. Standard two- to four-week courses were studied in the pre-biofilm era and against planktonic organisms.

Intracellular sequestration. Borrelia invades and survives within fibroblasts, macrophages, and neuronal cells. Doxycycline and amoxicillin achieve poor intracellular concentrations.

Morphological variation. Under antibiotic pressure, B. burgdorferi can convert to dormant, cell-wall-deficient cyst forms (round bodies) that are non-replicating, metabolically quiescent, and doxycycline-resistant. Metronidazole and tinidazole have activity against round body forms; standard protocols do not include them.

Primate models. Embers et al. (2012) demonstrated survival of Borrelia in Rhesus macaques following standard antibiotic courses, with organisms recoverable from multiple tissues by culture and PCR [8]. This is the most direct animal evidence of post-treatment persistence.

The IDSA’s response has consistently been to describe these findings as not applicable to human disease — a position that becomes difficult to defend when patient populations with post-treatment symptoms show serological, immunological, and clinical features consistent with active, not resolved, infection.

How the Dispute Became Institutionalized

The conflict hardened in 2006 when the IDSA published guidelines that were particularly dismissive of the PTLDS/persistent infection framework. Connecticut Attorney General Richard Blumenthal subsequently launched an antitrust investigation into the IDSA guideline panel, alleging that panel members had conflicts of interest and had systematically excluded physicians with dissenting views. The investigation concluded in 2008 with an agreement that the IDSA would convene a review panel.

The 2010 IDSA review panel upheld the original guidelines. Critics noted that it was composed of physicians who shared the original panel’s views and that the review process was designed to reach the same conclusion it did.

The result was a durable institutional schism. The IDSA guidelines are accepted by most US insurers and academic medical centers as the standard of care. Physicians who deviate from them, treating patients with longer courses or combination regimens, face insurance audits, board complaints, and in some states, loss of license.

ILADS remains the preferred framework for a substantial minority of Lyme-treating physicians, particularly those in clinical practice who see the full natural history of the disease rather than the limited slice that presents to academic referral centers after favorable initial response.

What the 2026 Evidence Landscape Looks Like

Since the most recent major RCTs, the literature has continued to develop in ways that complicate the simple “cured after two weeks” narrative.

A 2024 meta-analysis in Clinical Infectious Diseases found that 10–20% of patients treated for Lyme disease with guideline-concordant therapy continue to meet criteria for PTLDS at six months [9]. This is not a rare outcome and cannot be dismissed as hypochondria or misdiagnosis at scale.

Longitudinal proteomics and metabolomics studies have identified persistent immune activation signatures in post-treatment patients that differ from healthy controls and from patients with other inflammatory conditions, suggesting a biological basis for their symptoms that is not fully explained by the “resolved infection, residual inflammation” model.

Work from Johns Hopkins and the Global Lyme Alliance on drug combinations active against Borrelia persister cells — daptomycin, cephalosporins combined with stevia extract, disulfiram — has identified regimens with dramatically better activity against dormant forms than doxycycline alone [10]. This research stream makes no sense if persistence is not a real phenomenon.

What This Means for Patients

If you have been treated for Lyme disease and continue to have symptoms, the guideline dispute directly affects your care in the following ways:

Testing. Under IDSA-concordant practice, further Lyme testing is typically not offered if two-tier serology is negative or was previously positive and normalized. ILADS-oriented physicians may order supplementary tests including iSpot Lyme (a T-cell based assay), CD57 NK cell counts, co-infection panels, and inflammatory markers to build a more complete picture.

Treatment decisions. IDSA-aligned physicians will generally not offer extended antibiotic therapy and will redirect patients toward symptom management. ILADS-oriented physicians individualize treatment based on objective clinical findings, using combination regimens targeting different Borrelia morphological forms.

Insurance. Because IDSA guidelines are the insurer standard, extended antibiotic therapy is typically not covered. This creates access disparities: patients who can pay out of pocket, or who can travel to centers in Germany or other countries without the same prescribing restrictions, have treatment options unavailable to others.

The physician relationship. Patients should be aware that a physician following IDSA guidelines is not necessarily wrong or dismissive — they are following the formally endorsed standard of care. The standard of care is contested. Neither your symptoms nor the physician’s hesitance to treat is unreasonable; the system has failed to resolve a genuine scientific disagreement, and patients are caught in the middle.

My Clinical Position

After treating thousands of Lyme patients at St. George Hospital, my position is that Borrelia persistence is real in a clinically significant proportion of patients, that standard short-course therapy is insufficient for a meaningful minority, and that the IDSA guidelines underserve patients who fail initial treatment.

This does not mean that every patient with persistent symptoms has ongoing Borrelia infection. Post-infectious syndromes are real. Immune dysregulation can outlast the trigger. Co-infections — particularly Bartonella, Babesia, and Ehrlichia — may drive continued symptoms in patients who have adequately cleared Borrelia itself. Mold exposure, toxic burden, and reactivated herpesviruses (HHV-6, EBV, CMV) are common complicating factors that neither IDSA nor ILADS guidelines adequately address.

The physician’s job is to evaluate the whole patient. That means looking at the immune system, checking for co-infections and opportunistic pathogens, assessing inflammatory load, and working through the differential systematically — not applying a fixed protocol and attributing failure to the patient’s psychology.

Extended antibiotic therapy is one tool in that evaluation, appropriate for some patients, not all. It carries real risks, including microbiome disruption, Clostridioides difficile, and in IV form, biliary and venous complications. Those risks are real and must be weighed. But weighing them honestly means acknowledging that the alternative — undertreated persistent infection — also has costs that the IDSA framework does not adequately reckon with.

Related Articles

• Lyme Disease Treatment in Germany: What You Need to Know
• Combination Antibiotics for Lyme Disease: What the Tulane and Northwestern Research Means for PTLDS Patients
• Dapsone and Disulfiram Protocol for Persistent Lyme
• Hyperthermia vs Antibiotics for Lyme Disease: Comparing Outcomes
• Diagnostics: False Negatives in Lyme Testing